Twist Bioscience director Robert P. Ragusa received an annual stock award of 5,095 common shares on February 5, 2026. The shares were granted at a price of $0 per share, reflecting a typical equity compensation grant for a non-employee director.
According to the vesting terms, 100% of this annual equity award will vest on the earlier of one year from the grant date or the first annual stockholder meeting after the grant, as long as he continues serving as a director. Following this grant, Ragusa beneficially owns 28,983 Twist Bioscience common shares in total, held directly.
Twist Bioscience director Robert Chess reported a stock grant and updated his holdings. On February 5, 2026, he received an annual equity award of 5,095 shares of common stock at a price of $0 per share, increasing his directly held shares to 23,268.
The award vests in full on the earlier of one year from grant or the first stockholder meeting after the grant, so long as he continues as a service provider. He also beneficially owns 42,528 shares indirectly through the Chess 1997 Trust, where he and his spouse are the sole trustees and beneficiaries.
Twist Bioscience director Chan Nelson received an annual equity award of 5,095 shares of common stock on February 5, 2026. The award was granted at no cash cost per share and increased Nelson’s directly held stake to 33,251 shares.
The shares vest 100% on the earlier of the one-year anniversary of the grant date or the first annual stockholders’ meeting after the grant, as long as Nelson continues serving as a non-employee director on the applicable vesting date.
Twist Bioscience director Katryn Blake reported a new stock grant. On February 5, 2026, she acquired 5,095 shares of common stock at $0 per share as an annual equity award. Following this grant, she beneficially owns 19,448 common shares, held directly.
The award vests 100% on the earlier of the one-year anniversary of the grant date or the first annual stockholder meeting after the grant, as long as she continues serving as a non-employee director on the applicable vesting date.
Twist Bioscience director Jan Johannessen reported an equity award and related share sale. On 02/05/2026, Johannessen received 5,095 shares of common stock at $0. These annual equity award shares vest in full on the earlier of one year from grant or the first annual stockholder meeting, if he continues as a service provider.
On 02/06/2026, he sold 2,200 shares at $47.9067 per share to cover tax liabilities from restricted stock unit vesting, pursuant to a prior election rather than a discretionary trade. After these transactions, he directly owned 17,754 common shares.
William Blair Investment Management, LLC has filed Amendment No. 1 to a Schedule 13G reporting its ownership in Twist Bioscience Corp. As of the event date of 12/31/2025, the firm beneficially owned 5,954,429 shares of Twist Bioscience common stock, representing 9.7% of the outstanding class.
The filer reports sole voting power over 5,459,833 shares and sole dispositive power over 5,954,429 shares, with no shared voting or dispositive power. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of Twist Bioscience.
Twist Bioscience Corporation held its 2026 Annual Meeting of Stockholders, with strong participation from holders of 56,260,506 common shares, representing about 91.81% of shares eligible to vote. This high turnout indicates that most stockholders were represented, either in person or by proxy.
Stockholders elected three Class II directors to three-year terms: Keith Crandell, Jan Johannessen, and Trynka Shineman Blake. Blake received 50,217,493 votes for and 88,210 votes withheld, while Crandell and Johannessen each also secured substantial majorities, ensuring continuity on the board.
Investors approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 38,430,673 votes for, 11,842,367 against, and 32,663 abstentions, along with 5,954,803 broker non-votes. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending September 30, 2026, with 56,220,551 votes for, 18,170 against, and 21,785 abstentions.
A holder of the issuer’s common stock has filed a Form 144 notice to sell up to 2,200 common shares through Fidelity Brokerage Services LLC on the NASDAQ, with an aggregate market value of $105,394.74, around February 6, 2026.
The 2,200 shares were acquired on February 5, 2026 via restricted stock vesting from the issuer as compensation. Over the prior three months, the same holder sold 7,044 common shares on November 18, 2025 for gross proceeds of $174,479.88.
Twist Bioscience Corp's President and COO, Patrick John Finn, reported an automatic sale of common stock tied to equity compensation. On 02/03/2026, 2,705 shares of common stock were sold at $46.576 per share to cover tax withholding obligations from vesting restricted stock units. After this mandated "sell to cover" transaction under the company’s equity incentive plans, Finn beneficially owned 307,788 shares of Twist Bioscience common stock.
Twist Bioscience executive Dennis Cho reported a routine tax-related stock sale. On February 3, 2026, he sold 1,099 shares of Twist Bioscience common stock at $46.576 per share to cover tax withholding from vesting restricted stock units under the company’s equity plans.
After this mandated “sell to cover” transaction, Cho beneficially owned 143,581 shares of common stock in direct ownership. He serves as Senior Vice President, Chief Legal Officer & Corporate Secretary, and the filing notes these were not discretionary trades.